Tibial, Pedal, and Inframalleolar Disease
Tibial, pedal, and inframalleolar arterial disease taught around the threatened limb, the wound, and the perfusion required for healing rather than around every occluded segment. The chapter frames CLTI-anchored tibial revascularization, pedal access, and inframalleolar bypass and endovascular options.
Multidisciplinary board: A board-room discussion with roles, escalation triggers, surveillance, patient goals, and what makes the pathway coherent.
Choose the hostsStart with the wound question
Tibial, pedal, and inframalleolar arterial disease becomes clinically urgent when it is attached to a limb-threat problem: ischemic rest pain, gangrene, or an ulcer that has persisted for more than 2 weeks in the presence of objectively documented peripheral artery disease. The first task is therefore not to name every occluded tibial segment; it is to define the threatened limb, the wound, and the clinical consequence of failing to restore enough perfusion for healing. Current CLTI frameworks support urgent vascular-specialist referral, objective perfusion assessment, WIfI limb staging, and anatomic staging before committing to a revascularization strategy.
At the bedside, the opening question should be: “What tissue must heal, and what perfusion does that tissue need?” A plantar forefoot ulcer, a heel wound, toe gangrene, and diffuse diabetic foot sepsis are different clinical problems even when the angiogram shows the same tibial runoff pattern. The WIfI system is useful because it forces the surgeon to grade wound extent, ischemia, and infection together, rather than treating perfusion data as a stand-alone severity score.
This chapter’s anatomy is often the anatomy of diabetes, renal disease, and calcification: long tibial occlusions, diffuse calcified stenoses, total occlusions, multisegment disease, and lesions extending below the ankle. These features make tibial and pedal intervention technically demanding, but they do not change the clinical endpoint. The purpose of treatment is wound healing, relief of ischemic symptoms, preservation of function, and avoidance of major amputation where achievable.
A wound-directed strategy should not be reduced to a rigid angiosome rule. Direct revascularization to the wound territory is attractive when it is feasible and durable, but collateral pathways, pedal arch patency, tissue oxygenation, and patient-specific wound-bed perfusion may make an indirect route clinically meaningful. The practical teaching point is to ask whether the chosen artery can deliver usable perfusion to the wound, not merely whether it carries the correct anatomic name.
In patients with diabetes and foot ulceration, arterial planning must sit inside structured foot care. Perfusion assessment is one required component, alongside wound classification, offloading, infection control, wound healing care, prevention, and multidisciplinary coordination. A technically successful tibial procedure can still fail clinically if infection, pressure, or wound care are not controlled.
Perfusion data must answer a wound question
The ABI is often inadequate in the tibial-pedal CLTI patient, especially when diabetes and calcification make arteries poorly compressible. Current CLTI guidance prefers toe pressures over ABI in calcified or diabetic patients and integrates toe pressure and TcPO2 into hemodynamic assessment. The point is not to collect every possible test; it is to obtain objective perfusion data that can explain the wound and guide the need for revascularization.
Perfusion measurements should be interpreted in the same clinical frame as the wound. WIfI uses wound, ischemia, and infection axes to estimate amputation risk and the likely benefit of revascularization, replacing perfusion-only staging for limb-threat decisions. A mildly abnormal perfusion test in a clean superficial wound is not the same problem as the same measurement in a deep infected forefoot wound.
Objective data are especially important when bedside examination is unreliable. European and North American guideline frameworks continue to support toe pressure and TcPO2 assessment in CLTI, and the 2024 ACC/AHA guideline emphasizes combining objective perfusion testing with limb staging when tibial or pedal CLTI is suspected.
Anatomic data should be collected with the same discipline. GLASS staging was introduced to describe anatomic complexity for revascularization planning, including tibial and pedal disease; inframalleolar refinements further support the idea that below-the-ankle anatomy is not a minor detail but part of risk stratification and outcome prediction.
Perfusion data must also be used to expose nonarterial contributors to failure. A patient with PAD plus ulceration, neuropathy, infection, or pressure injury needs an integrated plan, not a perfusion number in isolation. When a wound does not improve after technically successful revascularization, the surgeon should revisit whether the wound bed received usable flow, whether infection and offloading were adequately addressed, and whether the original limb stage underestimated the problem.
Distal targets serve healing
The distal target is chosen to serve the wound. Current PAD guidance treats CLTI revascularization as standard care to minimize tissue loss and preserve limb function, and for nonhealing wounds or gangrene it supports strategies that achieve in-line flow or maximize wound-bed perfusion. In tibial and pedal disease, this means the angiographic endpoint should be judged by its ability to deliver blood to tissue that must heal.
- Population
- Patients with CLTI and infrainguinal PAD eligible for both strategies; cohort 1 had usable great saphenous vein.
- Intervention
- Provides the principal randomized evidence comparing surgical bypass with endovascular therapy in CLTI patients who have suitable vein for grafting.
- Comparator
- Endovascular therapy
- Key result
- BEST-CLI enrolled 1,830 CLTI patients with infrainguinal PAD; in cohort 1 with adequate single-segment great saphenous vein, MALE or death occurred in 42.6% after surgical bypass versus 57.4% after endovascular therapy over median 2.7 years (HR 0.68, 95% CI 0.59-0.79)
- Limitation
- Cohort 2 without adequate vein did not show the same significant difference.
Citation- Population
- Adults with CLTI requiring infra-popliteal revascularization (below-popliteal-trifurcation target).
- Intervention
- Use BASIL-2 as the modality reference point in tibial/pedal CLTI discussions; treat endovascular-first as the favored entry strategy when feasible, but balance against vein availability and operator experience for distal bypass.
- Comparator
- Vein bypass first
- Key result
- BASIL-2 (n=345 with CLTI requiring infra-popliteal revascularization) showed endovascular-first lowered the composite of major amputation or death versus vein-bypass-first (adjusted HR 1.35; P=0.037), making endovascular-first the favored opening strategy in this anatomy when feasible
- Limitation
- European pragmatic trial; cohort and conduit-eligibility populations differ from BEST-CLI Cohort 1. Endovascular-first does not exclude later bypass.
Citation- Population
- Adults with CLTI and infrapopliteal artery disease (tibial vessels) considered for endovascular treatment.
- Intervention
- LIFE-BTK is the contemporary pivotal RCT supporting drug-eluting resorbable scaffolds as a tibial endovascular option for CLTI with infrapopliteal disease when device access is feasible.
- Comparator
- 44%; absolute difference 30 percentage points; 95% CI 15-46; one-sided P<0.001),
- Key result
- LIFE-BTK (n=261 with CLTI and infrapopliteal disease) showed an everolimus-eluting resorbable scaffold was superior to angioplasty for the 1-year primary efficacy endpoint (74% event-free vs 44%; absolute difference 30 percentage points; 95% CI 15-46; one-sided P<0.001), and met non-inferiority for safety with a serious procedure-related adverse-event rate of 2% vs 3%
- Limitation
- Single-device RCT with industry sponsorship (Abbott); generalisability to multi-vessel infrapopliteal disease, longer follow-up, and other resorbable scaffolds remains to be defined. 12-month horizon only — durability beyond 1 year is being collected.
Citation- Population
- Adults with infrapopliteal CLTI considered for drug-coated balloon angioplasty.
- Intervention
- IN.PACT DEEP, with its negative 5-year result, remains the cautionary reference point for below-the-knee drug-coated balloon therapy. The LIFE-BTK drug-eluting scaffold offers a contemporary contrast within the same below-the-knee space.
- Comparator
- PTA
- Key result
- IN.PACT DEEP 5-year follow-up of paclitaxel-coated balloon versus PTA in infrapopliteal CLTI reported no durable patency benefit at 5 years and an early major-amputation signal that did not persist by trial end; the negative result has shaped current cautious interpretation of below-the-knee drug-coated balloon evidence
- Limitation
- Specific 5-year patency, TLR, amputation, and mortality percentages are inside the full-text tables/figures behind a subscription; rely on directional framing only until exact percentages are confirmed from the source tables.
Citation
Endovascular and surgical choices should be individualized rather than ideological. The guideline-level framework places patient risk, limb severity, anatomy, conduit, and local expertise at the center of strategy selection. In practice, this means that an endovascular-first plan may be appropriate for one infrapopliteal CLTI patient, while a bypass-first plan may be favored in another patient with usable vein and anatomy suitable for durable surgical inflow to the wound-related territory.
The randomized evidence is not one-note. In BEST-CLI, among CLTI patients with infrainguinal PAD and adequate single-segment great saphenous vein, major adverse limb event or death occurred less often after surgical bypass than after endovascular therapy over median 2.7 years; the cohort without adequate vein did not show the same significant difference. This supports careful conduit assessment before dismissing bypass in a good-risk patient with usable vein.
BASIL-2, focused on CLTI requiring infrapopliteal revascularization, found an endovascular-first strategy favored over vein-bypass-first for the composite of major amputation or death in that trial population. This should temper a reflexive bypass-first approach for all tibial disease, while also recognizing that BASIL-2 does not eliminate later bypass when endovascular therapy fails or when anatomy, wound status, and conduit make surgery the better salvage option.
Below-the-ankle and ultra-distal options are legitimate but should be framed honestly. Below-the-ankle angioplasty and inframalleolar bypass are supported by synthesis and cohort literature as part of the CLTI armamentarium, yet the clinical aim is often wound healing rather than indefinite vessel patency. In a small ultra-distal bypass series for tissue loss and complex tibial disease, freedom from graft failure at 12 months was 68%, freedom from major amputation was 92%, and most assessable ulcers healed by latest review; those numbers are encouraging but come from a small retrospective experience.
Device selection below the knee should remain device-specific and evidence-specific. IN.PACT DEEP did not demonstrate a durable 5-year patency benefit for infrapopliteal paclitaxel-coated balloon angioplasty and had an early major-amputation signal that did not persist by trial end, so femoropopliteal drug-balloon assumptions should not be imported wholesale below the knee. By contrast, LIFE-BTK showed a 1-year efficacy advantage for an everolimus-eluting resorbable scaffold over angioplasty in selected infrapopliteal CLTI patients, with noninferior safety, but longer-term durability and generalizability remain open.
Clinical integration, follow-up, and evidence boundaries
Successful care is measured at the foot, not only in the angiography suite. After tibial, pedal, or inframalleolar revascularization, follow-up must ask whether rest pain has improved, whether gangrene is demarcating or resolving, whether the ulcer is progressing toward healing, and whether infection and pressure have been controlled. The revascularization strategy is part of a multidisciplinary CLTI plan that includes antithrombotic therapy, wound care, diabetic foot care, and surveillance for clinical failure.
When a wound stalls, the first step is to return to the original wound question. Failure may reflect inadequate wound-bed perfusion, loss of the treated tibial or pedal route, poor collateral or pedal-arch support, uncontrolled infection, persistent pressure, or an anatomic plan that restored flow without serving the wound. Angiosome and woundosome concepts are useful here because they encourage the surgeon to examine both named arterial territories and patient-specific perfusion pathways.
Follow-up should also respect the limits of the evidence. BEST-CLI and BASIL-2 point in different directions because they studied different populations and strategy contexts: BEST-CLI’s strongest bypass signal was in patients with adequate single-segment great saphenous vein, whereas BASIL-2 specifically studied infrapopliteal revascularization and favored an endovascular-first approach in its cohort. The practical conclusion is not that one modality wins for all tibial disease, but that anatomy, conduit, limb stage, procedural risk, and institutional skill must be considered together.
Evidence boundaries are especially important in inframalleolar disease. Distal retrograde access, below-the-ankle angioplasty, inframalleolar bypass, drug-coated balloons, drug-eluting technologies, and resorbable scaffolds should not be discussed as interchangeable “BTK intervention.” Each has its own patient selection, technical role, and evidence base; some areas remain supported mainly by observational cohorts, subgroup analyses, or systematic reviews rather than definitive broad randomized data.
For the senior trainee, the durable habit is to document the full chain of reasoning: CLTI definition, wound and infection status, objective perfusion, WIfI stage, anatomic complexity, conduit status, intended wound-related target, and the follow-up endpoint that will define success. This discipline prevents the common failure mode of performing a technically elegant tibial procedure that does not answer the patient’s clinical problem.
References
- 1.2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS guideline for the management of lower extremity peripheral artery disease. Circulation. 2024.PubMed-indexed articleClinical practice guideline2024
2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS guideline for the management of lower extremity peripheral artery disease. Circulation. 2024. doi:10.1161/CIR.0000000000001251. PMID:38743805.
- 2.
- 3.
- 4.IWGDF Practical Guidelines on diabetes-related foot disease (Schaper et al, Diabetes Metab Res Rev 2024).PubMed-indexed articleClinical practice guideline2024
IWGDF Practical Guidelines on diabetes-related foot disease (Schaper et al, Diabetes Metab Res Rev 2024). doi:10.1002/dmrr.3657.
- 5.
- 6.
- 7.
- 8.
- 9.
- 10.
- 11.Drug-eluting stents for below-the-knee arterial disease. 2022.PubMed-indexed articleMeta-analysis / systematic review2022
Drug-Eluting Stents Versus Conventional Endovascular Therapies in Symptomatic Infrapopliteal Peripheral Artery Disease: A Meta-analysis. doi:10.1016/j.jscai.2022.100024. PMID:39132565.
- 12.
- 13.
- 14.
- 15.The angiosome and woundosome concepts in guiding revascularization for chronic limb-threatening ischemia and diabetic foot ulcers-a narrative review. Cardiovasc Diagn Ther. 2025.PubMed-indexed articleReview2025
The angiosome and woundosome concepts in guiding revascularization for chronic limb-threatening ischemia and diabetic foot ulcers-a narrative review. Cardiovasc Diagn Ther. 2025. doi:10.21037/cdt-2025-305.
- 16.Endovascular Recanalization for Infrapopliteal Artery Disease in Chronic Limb-Threatening Ischemia: A Practical Review. Vasc Specialist Int. 2025.PubMed-indexed articleReview2025
Endovascular Recanalization for Infrapopliteal Artery Disease in Chronic Limb-Threatening Ischemia: A Practical Review. Vasc Specialist Int. 2025. doi:10.5758/vsi.250076.
- 17.Ultra-distal bypass remains a valuable option for tibial disease with tissue loss. J Vasc Surg Cases Innov Tech. 2026.PubMed-indexed articleCase report2026
Ultra-distal bypass remains a valuable option for tibial disease with tissue loss. J Vasc Surg Cases Innov Tech. 2026. doi:10.1016/j.jvscit.2026.102157.
- 18.
- 19.
- 20.The Society for Vascular Surgery Lower Extremity Threatened Limb Classification System: risk stratification based on wound, ischemia, and foot infection (WIfI). J Vasc Surg. 2014.DOI publisher route2014
The Society for Vascular Surgery Lower Extremity Threatened Limb Classification System: risk stratification based on wound, ischemia, and foot infection (WIfI). J Vasc Surg. 2014. doi:10.1016/j.jvs.2013.08.003.
Educational use only
AI assists this editorial workflow. Published updates are human-reviewed before publication.
Not intended to diagnose, monitor, predict, prognose, treat, or alleviate disease.
Verify clinically relevant information against primary sources and current guidelines.